| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Rufloxacin HCl targets bacterial topoisomerases, specifically DNA gyrase (topoisomerase II) and topoisomerase IV, which are essential enzymes for bacterial DNA replication, transcription, and repair. By inhibiting these enzymes, rufloxacin prevents the supercoiling and relaxation of bacterial DNA, leading to inhibition of DNA replication and bacterial cell death. Rufloxacin also works on human monocytes and inhibits B cell differentiation.
|
|---|---|
| ln Vitro |
In vitro, rufloxacin HCl is a fluoroquinolone antibacterial agent with activity against a broad range of Gram-negative and some Gram-positive bacteria. It is active against S. aureus, E. coli, P. aeruginosa, P. morganii, K. pneumoniae, and E. cloacae in vitro (MICs = 0.78, 0.78...). It inhibits B-cell differentiation in human mononuclear cells. Rufloxacin shows photosensitizing properties toward biological substrates. In cell-based assays, rufloxacin inhibits bacterial growth in a dose-dependent manner.
|
| ln Vivo |
In vivo, rufloxacin HCl is a quinolone antibacterial agent. It is used as an antibiotic in research settings. However, specific in vivo data, such as efficacy in animal models of infection, are not detailed in the available literature. As a fluoroquinolone, it is expected to be effective against a range of bacterial infections, but further studies are needed to confirm its efficacy and safety.
|
| Enzyme Assay |
Non-cellular in vitro assays for rufloxacin HCl involve determining its minimum inhibitory concentration (MIC) against bacterial strains. A standard protocol uses the broth microdilution method. A series of two-fold dilutions of rufloxacin is prepared in 96-well plates. Bacterial inoculum (e.g., E. coli, S. aureus, P. aeruginosa) is added to each well. The plates are incubated at 37°C for 18-24 hours. The MIC is the lowest concentration of rufloxacin that inhibits visible bacterial growth. The compound's activity against a panel of bacterial strains is assessed.
|
| Cell Assay |
Cellular assays for rufloxacin HCl are performed using bacterial cell cultures. Bacteria are grown in liquid culture medium and treated with rufloxacin at various concentrations. Bacterial growth is measured by monitoring optical density at 600 nm (OD600) over time. The compound's bactericidal or bacteriostatic activity is assessed by plating serial dilutions of the treated cultures on agar plates and counting colony-forming units (CFU) after incubation. The minimum bactericidal concentration (MBC) is determined.
|
| Animal Protocol |
In vivo animal studies for rufloxacin HCl are conducted in rodent models of bacterial infection. Mice or rats are infected with a pathogenic bacterium (e.g., E. coli, S. aureus) via intraperitoneal or intravenous injection. Rufloxacin is administered orally or intravenously at doses such as 5-50 mg/kg. Survival rates, bacterial load in organs, and clinical signs of infection are monitored. The efficacy of rufloxacin is compared to other fluoroquinolones. However, specific published protocols are limited in the available literature.
|
| ADME/Pharmacokinetics |
Rufloxacin HCl has a molecular weight of 399.87 and a molecular formula of C17H18FN3O3S·HCl. It is a fluoroquinolone antibiotic. For in vivo studies, it can be formulated in standard vehicles. Detailed pharmacokinetic parameters such as half-life, bioavailability, and clearance have not been fully reported in the available literature. However, as a fluoroquinolone, it is expected to have good oral bioavailability and tissue penetration.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for rufloxacin HCl have not been extensively reported. As a research chemical, it is not intended for human use and is strictly for preclinical research purposes. Standard safety precautions should be followed when handling rufloxacin, including the use of personal protective equipment. Fluoroquinolones are known to have potential side effects including photosensitivity, tendon damage, and gastrointestinal disturbances. No specific LD50 values are available in the provided literature.
|
| Additional Infomation |
Rufloxacin HCl is a fluoroquinolone antibacterial agent active against a range of Gram-negative and Gram-positive bacteria. It works on human monocytes, inhibits B cell differentiation, and inhibits topoisomerase. Rufloxacin shows photosensitizing properties toward biological substrates. It is active against S. aureus, E. coli, P. aeruginosa, P. morganii, K. pneumoniae, and E. cloacae in vitro. Rufloxacin is not a clinically approved drug and has not entered recent clinical trials. Its primary application is in antimicrobial research.
|
| Molecular Formula |
C17H19CLFN3O3S
|
|---|---|
| Molecular Weight |
399.86
|
| Exact Mass |
399.082
|
| CAS # |
106017-08-7
|
| Related CAS # |
101363-10-4 (Parent)
|
| PubChem CID |
176015
|
| Appearance |
Light yellow to yellow solid powder
|
| Boiling Point |
574.6ºC at 760mmHg
|
| Melting Point |
322-324ºC
|
| Flash Point |
301.3ºC
|
| LogP |
2.501
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
608
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C(C1=O)=CN2CCSC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O.[H]Cl
|
| InChi Key |
LPQOADBMXVRBNX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18FN3O3S.ClH/c1-19-2-4-20(5-3-19)14-12(18)8-10-13-16(14)25-7-6-21(13)9-11(15(10)22)17(23)24;/h8-9H,2-7H2,1H3,(H,23,24);1H
|
| Chemical Name |
7-fluoro-6-(4-methylpiperazin-1-yl)-10-oxo-4-thia-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid;hydrochloride
|
| Synonyms |
Rufloxacin HCl MF 934 Rufloxacin Hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~2 mg/mL (~5.00 mM)
DMSO : ~0.0852 mg/mL (~0.21 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5009 mL | 12.5044 mL | 25.0088 mL | |
| 5 mM | 0.5002 mL | 2.5009 mL | 5.0018 mL | |
| 10 mM | 0.2501 mL | 1.2504 mL | 2.5009 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
